Intermune CEO asks Supreme Court to review off-label marketing conviction

08/12/2013 | PharmaLive.com

Former Intermune CEO W. Scott Harkonen is asking the Supreme Court to review his conviction for wire fraud in a case involving off-label marketing of Actimmune. Harkonen issued a press release stating that a clinical trial confirmed Actimmune's efficacy against idiopathic pulmonary fibrosis, though the drug was not FDA-approved for that indication. Harkonen asserts that the conviction violates his right to free speech and that the statements he made were not false or misleading.

View Full Article in:

PharmaLive.com

Published in Brief:

SmartBrief Job Listings for Health Care